| Gao Hanjing,Tao Zhen,Wang Huanhuan,Li Fengtong,Dong Yang,Yu Xuyao,Wang Jingsheng,Chen Huaming,Song Yongchun,Yuan Zhiyong.Preliminary clinical study on treatment of prostate cancer with Cyber-Knife[J].Chinese Journal of Radiological Medicine and Protection,2019,39(6):415-421 |
| Preliminary clinical study on treatment of prostate cancer with Cyber-Knife |
| Received:January 04, 2019 |
| DOI：10.3760/cma.j.issn.0254-5098.2019.06.003 |
| KeyWords:Ultra-hypofractionated Stereotactic body radiotherapy Cyber-Knife Prostate cancer Prostate-specific antigen |
| FundProject: |
| Author Name | Affiliation | E-mail | | Gao Hanjing | Department of Radiotherapy, Tianjin 4th Centre Hospital, Tianjin 300140, China | | | Tao Zhen | Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300100, China | | | Wang Huanhuan | Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300100, China | | | Li Fengtong | Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300100, China | | | Dong Yang | Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300100, China | | | Yu Xuyao | Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300100, China | | | Wang Jingsheng | Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300100, China | | | Chen Huaming | Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300100, China | | | Song Yongchun | Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300100, China | | | Yuan Zhiyong | Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300100, China | zyuan@tmu.edu.cn |
|
| Hits: 2822 |
| Download times: 1412 |
| Abstract:: |
| Objective To evaluate the safety and effectiveness of ultra-hypofractionated stereotactic body radiotherapy in the treatment of prostate cancer. Methods A total of 26 patients with prostate cancer treated with Cyber-Knife from May 2010 to May 2018 were analyzed retrospectively. The median age of the patients was 69 years old (range, 57 to 87). Ultra-hypofractionated radiotherapy was delivered in five fractions of 7.0-7.5 Gy for a total dose of 35.0-37.5 Gy. Androgen deprivation therapy (ADT) was administered in combination with the Cyber-Knife. The primary endpoints were radiation toxicity, PSA-response, local control and symptom alleviation, while the secondary endpoints were progression-free survival and overall survival. Results No graded ≥ 3 acute and late radiation toxicities occurred during follow-up. The acute toxicity of Grades 1 and 2 was 38.4% and 19.2%, while the late toxicity of Grades 1 and 2 was 30.8% and 3.8%,respectively. At a median follow-up of 22.44 months, for patients with localized stage, PSA level was decreased significantly after radiotherapy (Z=2.900, 2.794, 2.510, 2.090, P<0.05). However, there was no statistically significant difference for the metastatic group (P>0.05). Conclusions Ultra-hypofractionated stereotactic body radiotherapy is a safe and effective treatment for patients with prostate cancer. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
